Hydrogel News and Research

RSS

Oculus launches Microcyn Skin & Wound HydroGel OTC

Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.

29 Sep 2009

Biomaterial gel for treating spinal cord injury

Research led by a scientist at the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has shown injecting biomaterial gel into a spinal cord injury site provides significantly improved healing.

18 Sep 2009

Six research project grants aimed at improving human health awarded

Six research project grant awards totaling $5.1 million will be made to Washington life sciences organizations and their partners, the state’s Life Sciences Discovery Fund announced today.

16 Sep 2009

New hydrogel mats extends anti-infection protection

Treatment of hospital-related infections in the U.S. costs up to $11 billion a year and about half of those infections are related to medical devices implanted in patients. Until now, efforts to control drug-resistant biofilms on such devices have been largely unsuccessful.

15 Sep 2009

Oculus Innovative Sciences Receives Medicare HCPCS Code For Reimbursement Of Microcyn® Skin & Wound Hydrogel

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, announced today that Noridian Administrative Services LLC, which is the pricing, data analysis and coding contractor for the Medicare program with respect to durable medical equipment, prosthetics, orthotics, and medical supplies, has assigned a Medicare HCPCS code for Oculus’ recently introduced Microcyn Skin & Wound HydroGel.

11 Sep 2009

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Asset Purchase Agreement Signed for Marketed Prescription Products Desonate(R) and NeoBenz(R) Micro

3 Sep 2009

USPTO awards two new patents to Nerites

Nerites Corporation announced Thursday that the United States Patent and Trademark Office (USPTO) issued two new patents covering the company’s technology. These “composition of matter” patents provide underlying intellectual property protection for surgical adhesives, films, and coatings. Nerites’ scientists create synthetic mimetics of the protein components used by marine mussels to stick to rocks under water.

28 Aug 2009

Sigma-Aldrich offers customizable synthetic extracellular matrix (ECM) for stem cell research

Sigma-Aldrich (Nasdaq: SIAL) today announced an agreement with Glycosan BioSystems for the sale of HyStem(TM), a fully customizable synthetic extracellular matrix (ECM) for stem cell research. HyStem offers researchers flexibility to tailor microenvironments for their cultured cells that mimic natural in vivo conditions, optimizing stem cell proliferation and differentiation. HyStem was developed by Glycosan BioSystems and will be sold by Sigma-Aldrich under a non-exclusive distribution agreement.

13 Aug 2009

New bio-hybrid materials could be used as sensors, catalysts, drug-delivery systems, more

Bacteria play a role in myriad industrial processes from fermentation to cleaning up environmental pollution. But floating freely in solution, the microbial cells constantly multiply, generating biomass that must be removed periodically, causing downtime. Additionally, the microorganisms cannot be localized to a specific region of interest.

3 Aug 2009

Dynamic, 3D pattern formation within protein-based gel

Modern regenerative medicine is on the lookout for implantable materials that can change as the surrounding tissue does, and two Stanford University researchers have made some new gel materials that do just that. Karin Straley and Professor Sarah Heilshorn have developed a method for preparing protein-based implant materials that can evolve with the changing needs of the host biological system. Not only can their new materials change in different ways at different times, they can do so at different places within the implant materials.

31 Jul 2009

Protein biochips

Biochips carrying thousands of DNA fragments are widely used for examining genetic material. Experts would also like to have biochips on which proteins are anchored. This requires a gel layer which can now be produced industrially.

24 Jun 2009

Research looks at contact lens risks and benefits

Contact lenses are great for sight, but do they have an impact on general eye health? Researchers at the University of Alabama at Birmingham (UAB) School of Optometry are working to answer that question by analyzing tears.

6 May 2009

Nanoparticles applied to skin offer hope for erection problems

Cutaneous application of nanoparticles may offer a new means of delivering drugs to treat erectile dysfunction (ED), according to findings presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).

26 Apr 2009

Discovery of 'lock-like' molecule may provide new ways to starve cancer tumors or prevent drug side effects

Scientists have shed new light -- literally -- on a possible way to starve cancer tumors or prevent side effects from a wide range of drugs.

30 Mar 2009

Study looks at maggot therapy on wound healing

Larval (maggot) therapy has similar health benefits and costs compared with a standard treatment for leg ulcers, find two studies published on bmj.com.

20 Mar 2009

A nanotech coating for brain implants

Biomedical and materials engineers at the University of Michigan have developed a nanotech coating for brain implants that helps the devices operate longer and could improve treatment for deafness, paralysis, blindness, epilepsy and Parkinson's disease.

11 Mar 2009

Angiotech Pharmaceuticals announces positive results from Bio-Seal study

Angiotech Pharmaceuticals, Inc. has announced positive clinical study results for its Bio-Seal Lung Biopsy Tract Plug System at the Society of Interventional Radiologists Annual Scientific Meeting in San Diego, CA.

11 Mar 2009

Endo Pharmaceuticals to acquire Indevus Pharmaceuticals

Endo Pharmaceuticals (NASDAQ:ENDP) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.

5 Jan 2009

First U.S. implants of Embozene color-advanced microspheres embolization technology

Against the backdrop of a flagging economy, bailouts, and bleak predictions, there is a biotechnology firm in suburban Atlanta with a future as bright as New Year's Eve fireworks.

1 Jan 2009

Coated lenses set to reduce 'post-op' infections for cataract patients

Research presented at the British Pharmaceutical Conference (BPC) in Manchester reveals that coating an artificial lens with antibiotics could significantly reduce the risk of post-operative infection, and even blindness, for cataract patients.

7 Sep 2008